Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for Jennifer Yang�
7.55
+0.19 (2.58%)
Real-time:   11:06AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.39 - 7.80
52 week 6.33 - 15.56
Open 7.40
Vol / Avg. 355,016.00/638,135.00
Mkt cap 457.46M
P/E     -
Div/yield     -
EPS -0.79
Shares 60.59M
Beta 2.72
Inst. own 29%
Feb 9, 2015
Inovio Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Inovio Pharmaceuticals Inc at Emerald Research Groundhog Day Investment Forum
Jan 12, 2015
Inovio Pharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -390.09% -490.69%
Operating margin -452.69% -145.12%
EBITD margin - -139.17%
Return on average assets -20.81% -99.06%
Return on average equity -24.13% -152.12%
Employees 71 -
CDP Score - -

Address

10480 WATERIDGE CIRCLE
SAN DIEGO, CA 92121
United States - Map
+1-858-5976006 (Phone)
+1-267-4404242 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inovio Pharmaceuticals, Inc. (Inovio) is advancing a portfolio of deoxyribonucleic acid (DNA) vaccines, also known as immunotherapies, to prevent or treat cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Its immunotherapies activate immune responses to prevent and treat disease. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, United States Military HIV Research Program, and University of Manitoba.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Jennifer Laux Vice President - Commercial
Bio & Compensation  - Reuters
Zane Yang Vice President - Clinical Development, Oncology
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 69
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Mort Collins Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters